Lv3
250 积分 2025-09-19 加入
Efficacy and safety of a targeted-release formulation of budesonide in patients with primary IgA nephropathy (NefIgArd): 2-year results from a randomised phase 3 trial
1个月前
已完结
Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial
1个月前
已完结
Ten unanswered questions about dipeptidyl peptidase-1 inhibition in bronchiectasis
1个月前
已关闭
皖公网安备34019202002308
